New Vaccine-Like therapy targets ovarian Cancer's weak spots

NCT ID NCT03839524

First seen Nov 15, 2025 · Last updated May 12, 2026 · Updated 23 times

Summary

This early-stage trial tested a personalized immunotherapy called TG4050 in 64 women with advanced ovarian, fallopian tube, or peritoneal cancer who had completed standard chemotherapy and were in remission. The treatment aims to train the immune system to recognize and attack cancer cells based on each patient's unique tumor mutations. The main goal was to check safety and tolerability, with secondary goals measuring tumor response and CA-125 levels.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVARIAN CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Hôpital Pitié-Salpêtrière

    Paris, 75013, France

  • IUCT Toulouse

    Toulouse, 31100, France

  • Institut Curie

    Paris, 75005, France

  • Mayo Clinic Jacksonville

    Jacksonville, Florida, 32224, United States

  • Mayo Clinic Phoenix

    Phoenix, Arizona, 85259, United States

  • Mayo Clinic Rochester

    Rochester, Minnesota, 55905, United States

Conditions

Explore the condition pages connected to this study.